Jordi Ferrer-Playan

Statistics

Publications

Citations

105

H-Index

Active since

2021

Affiliations

Merck KGaA, Darmstadt (Germany)(Current)

Sarah Cannon Research Institute

The Christie NHS Foundation Trust

Dana-Farber Cancer Institute

University of Manchester

Jordi Ferrer-Playan is an author at Merck KGaA, Darmstadt (Germany) specializing in cancer pharmacology, chemotherapy, and ataxia telangiectasia and rad3-related inhibition.

Publications per year

2021–2024

Publications

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

Melinda L. Telli, Sara M. Tolaney, Geoffrey I. Shapiro et al. · npj Breast Cancer · 2022 · 38 citations · Full text

Medicine, Oncology, Pharmacology +15

A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours

Howard A. Burris, Jordan Berlin, Hendrik‐Tobias Arkenau et al. · British Journal of Cancer · 2024 · 34 citations · Full text

Medicine, Oncology, Pharmacology +14

A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer

Ruth Plummer, Emma Dean, Hendrik‐Tobias Arkenau et al. · Lung Cancer · 2021 · 33 citations · Full text

Medicine, Oncology, Pharmacology +15

1–3 of 3